
Sign up to save your podcasts
Or


Key Takeaways:
How the $6M social media bellwether verdict breaks down and what the liability split means
Why the Dupixent MDL is expected to be a smaller, high-quality docket rather than a volume play
What makes Depo-Provera the fastest-moving mass tort in recent history and what to watch next
Why the preemption argument in Depo-Provera is widely expected to fail and what happens after
Which GLP-1 medications are now specifically tied to NA-ION vision loss based on new study data
How parallel state and federal tracks are shaping the GLP-1 litigation strategy
By Jon & MarcKey Takeaways:
How the $6M social media bellwether verdict breaks down and what the liability split means
Why the Dupixent MDL is expected to be a smaller, high-quality docket rather than a volume play
What makes Depo-Provera the fastest-moving mass tort in recent history and what to watch next
Why the preemption argument in Depo-Provera is widely expected to fail and what happens after
Which GLP-1 medications are now specifically tied to NA-ION vision loss based on new study data
How parallel state and federal tracks are shaping the GLP-1 litigation strategy